»MORE: Trump reveals he is taking hydroxychloroquine to prevent infection
"Angiotensin-converting enzyme 2 (ACE2) has been generally accepted by the scientific community as a receptor required for the entry of SARS-CoV-2 into human cells," said Dr. Igor Kovalchuk, CEO of Pathway Rx and holder of a Health Canada License for Cannabis Research. He added that, "Our initial findings warrant further investigation but it's possible that medical cannabis products could become a safe adjunct therapy for the treatment of COVID-19."
The study results were recently shared publicly, and the research paper was submitted to a scientific journal for peer review, according to Pathway Rx.
Among the 1,000 Cannabis sativa varieties that have been screened by Pathway Rx, only a small number have expressed medicinal properties. The research company is seeking funding to continue its efforts to support scientific initiatives to address COVID-19.
“The Government of Canada’s latest investment to support the health of Canadians creates a significant opportunity for Pathway Rx to advance our research and accelerate the development of custom therapies and products to help combat COVID-19,” Kovalchuk said in a statement.
The results come as several countries lean upon the science community for answers on how to prevent and treat COVID-19. On Monday, President Donald Trump announced that for at least two weeks he’s explored the drug hydroxychloroquine as a preventive measure against the coronavirus. He also shared that frontline workers are taking the drug, which has been found by the FDA to cause serious heart problems.
Controversy continues to surround the medical solutions that have been purported as options to curb the spread of the virus, which, as of May 19, claimed the lives of more than 90,000 Americans and nearly 325,000 people across the globe.